Loading

logo

Journal of Neurobiology and Physiology

ISSN: 2692-546X

Commentary Open Access
Volume 4 | Issue 1 | DOI: https://doi.org/10.46439/neurobiology.4.019

The surgical philosophy for the management of rathke cleft cyst: Finding the sweet spot

Alaa S. Montaser1, Edward R. Laws2,*
  • 1Department of Neurosurgery, Mayo Clinic, Jacksonville, Florida, USA
  • 2Department of Neurosurgery, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
+ Affiliations - Affiliations

Corresponding Author

Edward R. Laws, elaws@bwh.harvard.edu

Received Date: January 23, 2022

Accepted Date: March 11, 2022

Citation:

Montaser AS, Laws ER. The surgical philosophy for the management of rathke cleft cyst: Finding the sweet spot. J Neurobiol Physiol. 2022;4(1):1-3.


Copyright: © 2022 Montaser AS, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Rathke cleft cysts (RCC) are the embryological remnants of the pars intermedia within the Rathke’s pouch, and they represent the benign end of a spectrum of lesions originating from this region. RCCs are commonly small asymptomatic lesion; however, they often attain large size and exert mass effect on surrounding vital neurovascular structures, and hence become symptomatic. RCCs are the target of transsphenoidal surgery when symptomatic; however, surgical management of RCC is challenging, because aggressive resection may carry a high risk of complications - commonly diabetes insipidus (DI), due to the embryological proximity to the neurohypophysis – whereas sub-optimal resection may result in higher rates of cyst recurrence. In this commentary, we highlight nuances in diagnosis, and our philosophy to optimize surgical treatment of RCCs.

Keywords

Rathke cleft cyst, Cystic pituitary lesions, Cystic sellar lesions, Endoscopic transsphenoidal surgery, Diagnosis

Recommended Articles

Immune checkpoint inhibitor therapy-associated myocarditis – Toward identification of an immune signature that can improve diagnosis

Immune checkpoint inhibitors (ICI) have emerged as promising treatment options for many cancers. ICIs exert their therapeutic effects by targeting immune inhibitory molecules on T-cells in adaptive immunity, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1). ICIs, however, can result in a wide variety of immune-related adverse events (iRAE), including myocarditis, a rare and potentially deadly complication that necessitates early diagnosis.

Machine learning methods for prostate cancer diagnosis

Prostate cancer (Pca) is one of the most common cancers among men worldwide. The current screening methods lack effectiveness such as prostate-specific antigen (PSA) and Magnetic resonance imaging (MRI), and some others come with pain such as biopsy. Understanding the genomic behavior of the disease may play a key part in designing more effective, accurate, and less invasive diagnosis measures. Pca has many clinical features to describe the spread and the aggressiveness of the tumor including Gleason score, TNM staging system, and the location of the tumor in the prostate gland which is known as laterality.

Full Text
Cite
Download PDF
Author Information X